DE69334350D1 - P- Selectin Ligandenprotein - Google Patents
P- Selectin LigandenproteinInfo
- Publication number
- DE69334350D1 DE69334350D1 DE69334350T DE69334350T DE69334350D1 DE 69334350 D1 DE69334350 D1 DE 69334350D1 DE 69334350 T DE69334350 T DE 69334350T DE 69334350 T DE69334350 T DE 69334350T DE 69334350 D1 DE69334350 D1 DE 69334350D1
- Authority
- DE
- Germany
- Prior art keywords
- selectin ligand
- ligand protein
- disclosed
- selectin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 108010054395 P-selectin ligand protein Proteins 0.000 title abstract 4
- 102000008212 P-Selectin Human genes 0.000 abstract 2
- 108010035766 P-Selectin Proteins 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 108090000288 Glycoproteins Proteins 0.000 abstract 1
- 102000003886 Glycoproteins Human genes 0.000 abstract 1
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000005732 intercellular adhesion Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6454—Dibasic site splicing serine proteases, e.g. kexin (3.4.21.61); furin (3.4.21.75) and other proprotein convertases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
- C07K16/2854—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1051—Hexosyltransferases (2.4.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Transplantation (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US96566292A | 1992-10-23 | 1992-10-23 | |
US11260893A | 1993-08-26 | 1993-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
DE69334350D1 true DE69334350D1 (de) | 2011-04-21 |
Family
ID=26810148
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69333346T Expired - Lifetime DE69333346T2 (de) | 1992-10-23 | 1993-10-22 | Neuartiges p- selectin ligandenprotein |
DE69334350T Expired - Lifetime DE69334350D1 (de) | 1992-10-23 | 1993-10-22 | P- Selectin Ligandenprotein |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE69333346T Expired - Lifetime DE69333346T2 (de) | 1992-10-23 | 1993-10-22 | Neuartiges p- selectin ligandenprotein |
Country Status (9)
Country | Link |
---|---|
EP (2) | EP0666914B1 (de) |
JP (3) | JPH08502886A (de) |
AT (2) | ATE501254T1 (de) |
AU (1) | AU677261B2 (de) |
CA (2) | CA2497857C (de) |
DE (2) | DE69333346T2 (de) |
DK (2) | DK0666914T3 (de) |
PT (1) | PT666914E (de) |
WO (1) | WO1994010309A1 (de) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6124267A (en) * | 1991-02-05 | 2000-09-26 | Southpac Trust Internationals, Inc. | O-glycan inhibitors of selectin mediated inflammation derived from PSGL-1 |
US6277975B1 (en) | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
US5843707A (en) * | 1992-10-23 | 1998-12-01 | Genetics Institute, Inc. | Nucleic acid encoding a novel P-selectin ligand protein |
WO1995030001A2 (en) * | 1994-04-28 | 1995-11-09 | Genetics Institute, Inc. | Novel p-selectin ligand protein |
AU770883B2 (en) * | 1996-08-30 | 2004-03-04 | Genetics Institute, Llc | P-selectin ligand proteins |
US7399847B1 (en) * | 1996-11-25 | 2008-07-15 | The General Hospital Corporation | Nucleic acids encoding artificial P-selectin ligands |
SE9701127D0 (sv) | 1997-03-26 | 1997-03-26 | Karolinska Innovations Ab | Antigenic fusionprotein carrying GALal, 3GAL epitopes |
AU2975599A (en) * | 1998-02-27 | 1999-09-15 | Genetics Institute Inc. | P-selectin ligand protein including tetrameric fusion proteins |
WO2000025808A1 (en) * | 1998-10-30 | 2000-05-11 | Genetics Institute, Inc. | Inhibition of differentiation of cytotoxic t-cells by p-selectin ligand (psgl) antagonists |
NZ521686A (en) | 2000-03-24 | 2005-03-24 | Genetics Inst | A member of the selectin ligand interactor cytoplasmic (SLIC-1) protein familys |
DK1681299T3 (da) * | 2000-03-27 | 2010-02-01 | Genetics Inst Llc | Fremgangsmåde til rensning af højt anioniske proteiner |
EP1325123A4 (de) * | 2000-09-12 | 2004-07-21 | Inst Genetics Llc | Stenose- bzw. restenosehemmung durch p-selectin-antagonisten |
WO2003088996A2 (en) * | 2002-04-22 | 2003-10-30 | Recopharma Ab | Lewis y epitope modified polypeptide, or mucin fusion polypetide, tumor vaccines |
WO2004012817A2 (en) * | 2002-07-31 | 2004-02-12 | Kylix B.V. | Use of genes identified to be involved in tumor development for the development of anti-cancer drugs |
WO2007022799A1 (en) | 2005-08-26 | 2007-03-01 | Ares Trading S.A. | Process for the preparation of glycosylated interferon beta |
EP1960419B1 (de) | 2005-12-09 | 2016-03-16 | Ares Trading S.A. | Verfahren zur aufreinigung von fsh oder einer fsh-mutante |
US20070160601A1 (en) * | 2005-12-09 | 2007-07-12 | Angela Widom | Neutralizing antibodies against primate psgl-1 and uses therefor |
US20100249381A1 (en) * | 2007-10-22 | 2010-09-30 | David Delvaille | Method for Purifying FC-Fusion Proteins |
WO2009139459A1 (ja) * | 2008-05-15 | 2009-11-19 | 国立大学法人 岡山大学 | Psgl-1阻害によるメタボリックシンドロームの予防及び治療法 |
CN114767858A (zh) * | 2014-07-08 | 2022-07-22 | 桑福德伯纳姆医学研究所 | Psgl-1调控剂及其用途 |
US11306150B2 (en) | 2017-01-11 | 2022-04-19 | Bristol-Myers Squibb Company | Method of identifying a P-selectin glycoprotein ligand-1 (PSGL-1) antagonist |
BR112019019108A2 (pt) | 2017-03-14 | 2020-04-22 | Five Prime Therapeutics, Inc. | anticorpos, ácido nucleico, composições, célula, métodos para preparar de um anticorpo, para tratar um sujeito com câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para identificar um ab, para melhorar a eficácia antitumoral de um ab, para melhorar a farmacocinética de um anticorpo, para seleção de um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos e para detectar vista em uma amostra |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US4675285A (en) | 1984-09-19 | 1987-06-23 | Genetics Institute, Inc. | Method for identification and isolation of DNA encoding a desired protein |
US4737323A (en) | 1986-02-13 | 1988-04-12 | Liposome Technology, Inc. | Liposome extrusion method |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
JPH05504470A (ja) * | 1989-10-20 | 1993-07-15 | ニューイングランド・メディカル・センター・ホスピタルズ・インコーポレーテッド | Padgemを介した細胞結合の阻害 |
ATE224911T1 (de) * | 1990-07-17 | 2002-10-15 | Univ Oklahoma | Gmp-140 ligand |
ATE158816T1 (de) | 1990-11-26 | 1997-10-15 | Genetics Inst | Expression von pace in wirtszellen und verfahren zu dessen verwendung |
EP0575557A1 (de) * | 1991-03-11 | 1993-12-29 | New England Medical Center | Verfahren zur hemmung von padgem-vermittelter interaktionen unter verwendung von einer 2,6-sialinsäure |
CA2108029A1 (en) * | 1991-05-06 | 1992-11-07 | Laurence A. Lasky | Glycam-1(sgp 50), a selectin ligand |
WO1994011498A1 (en) * | 1992-11-16 | 1994-05-26 | Board Of Regents Of The University Of Oklahoma | Glycoprotein ligand for p-selectin and methods of use thereof |
-
1993
- 1993-10-22 EP EP94900380A patent/EP0666914B1/de not_active Expired - Lifetime
- 1993-10-22 CA CA002497857A patent/CA2497857C/en not_active Expired - Lifetime
- 1993-10-22 DE DE69333346T patent/DE69333346T2/de not_active Expired - Lifetime
- 1993-10-22 WO PCT/US1993/010168 patent/WO1994010309A1/en active IP Right Grant
- 1993-10-22 EP EP03025430A patent/EP1396542B1/de not_active Expired - Lifetime
- 1993-10-22 AT AT03025430T patent/ATE501254T1/de active
- 1993-10-22 AT AT94900380T patent/ATE256182T1/de active
- 1993-10-22 JP JP6511208A patent/JPH08502886A/ja active Pending
- 1993-10-22 AU AU55388/94A patent/AU677261B2/en not_active Expired
- 1993-10-22 DK DK94900380T patent/DK0666914T3/da active
- 1993-10-22 DE DE69334350T patent/DE69334350D1/de not_active Expired - Lifetime
- 1993-10-22 DK DK03025430.4T patent/DK1396542T3/da active
- 1993-10-22 PT PT94900380T patent/PT666914E/pt unknown
- 1993-10-22 CA CA002147623A patent/CA2147623C/en not_active Expired - Lifetime
-
2004
- 2004-01-16 JP JP2004008944A patent/JP3668242B2/ja not_active Expired - Fee Related
-
2005
- 2005-01-27 JP JP2005019879A patent/JP4237711B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
CA2147623C (en) | 2005-05-03 |
JP2005170954A (ja) | 2005-06-30 |
AU677261B2 (en) | 1997-04-17 |
ATE501254T1 (de) | 2011-03-15 |
EP1396542A2 (de) | 2004-03-10 |
ATE256182T1 (de) | 2003-12-15 |
WO1994010309A1 (en) | 1994-05-11 |
JPH08502886A (ja) | 1996-04-02 |
DK1396542T3 (da) | 2011-06-06 |
DE69333346D1 (de) | 2004-01-22 |
EP0666914A1 (de) | 1995-08-16 |
AU5538894A (en) | 1994-05-24 |
JP4237711B2 (ja) | 2009-03-11 |
EP1396542B1 (de) | 2011-03-09 |
DK0666914T3 (da) | 2004-04-13 |
CA2497857A1 (en) | 1994-05-11 |
CA2497857C (en) | 2009-05-26 |
JP2004194664A (ja) | 2004-07-15 |
PT666914E (pt) | 2004-04-30 |
CA2147623A1 (en) | 1994-05-11 |
JP3668242B2 (ja) | 2005-07-06 |
DE69333346T2 (de) | 2004-10-07 |
EP1396542A3 (de) | 2004-05-06 |
EP0666914B1 (de) | 2003-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE501254T1 (de) | P- selectin ligandenprotein | |
CA2263889A1 (en) | P-selectin ligand proteins | |
SE8105657L (sv) | Mikrobiell framstellning av humanfibroblastinterferon | |
ATE118821T1 (de) | Nukleotidesequenzen, die ein protein mit ureareaktivität kodieren. | |
DK164940C (da) | Polypeptid med human-gamma-interferonaktivitet, genteknologisk fremgangsmaade til fremstilling deraf, hybrid-plasmider indeholdende en dna-sekvens, der koder for peptidet, vaertsorganismer indeholdende hybridplasmiderne, samt laegemidler, som indeholder polypeptidet | |
IL89938A0 (en) | Viper venom polypeptides,their purification and genetic expression | |
FI90667C (fi) | Menetelmä valmistaa uutta ihmisen tyypin I interferoniproteiinia | |
GR3024379T3 (en) | Peptides with organo-protective activity, the process for preparing them and their use in therapy | |
WO1995030001A3 (en) | Novel p-selectin ligand protein | |
EP0641215A4 (de) | Protease-resistente analoge des thrombomodulin. | |
EP0967283A4 (de) | Gene, die für proteine mit transglykolysierungsaktivität kodieren. | |
FR2607517B2 (fr) | Vecteurs d'expression de variants de l'hirudine dans les levures, procede et produit obtenu | |
DE3881023D1 (de) | Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten. | |
HUT50195A (en) | New peptites hindering the activity of immune system and medical compositions containing them and process for production of these peptides and compositions | |
DK38889A (da) | Onkogen-indkodet polypeptid med vaekstfaktoraktivitet | |
EP0310887A3 (en) | Vasoconstrictor peptide | |
ATE109827T1 (de) | Verfahren zur herstellung von peptiden, dazu zu verwendendes rekombinantes plasmid und mit diesem plasmid transformierte myelomzellen. | |
AU7880987A (en) | Human B-cell differentiation factor and process of producing said factor | |
DE69115270D1 (de) | Protein mit fibroblasten-wachstumsfaktor-rezeptoraktivität. | |
WO1999043834A3 (en) | P-selectin ligand protein, including tetrameric fusion proteins | |
WO1990000179A3 (fr) | Nouvelles proteins, adn les codant et leur usage | |
ATE102997T1 (de) | Thymosin und tnf-kodierende dna. | |
ATE91303T1 (de) | Verfahren zur herstellung von peptiden durch spezifische spaltung von gentechnisch gewonnenen fusionsproteinen mit collagenasen. |